Cosmos Health Reports Q2 2026 Results: Record Q2 and H1 Revenue of $19.0M and $36.9M, Up 29% and 30%; Q2 Adjusted Gross Profit Up 58%; Total Liabilities Reduced 13%; Stockholders' Equity Up 12%; $5M Share Repurchase Program Underway
Cosmos Health reported record second-quarter revenue of $18.99 million, up 29% year-over-year, and a record first half of $36.91 million, driven by growth across all core divisions including Decahedron, Cana Laboratories, and CosmoFarm. Operational metrics improved significantly, with adjusted gross profit rising 58% to $1.84 million and adjusted gross margin expanding 165 basis points to 9.54%, while operating expenses grew at roughly half the rate of revenue.
Key figures
- Revenue
- $18.99 million
- Revenue Yoy
- 28.8%
- H1 revenue
- $36.91 million
- H1 revenue yoy
- 29.7%
- Adjusted ebitda q2
- -$1.13 million
- Stockholders equity
- $20.67 million
- Buyback authorization
- $5.0 million
- Shares repurchased q2
- 2650000
- Adjusted gross margin q2
- 9.54%
- Adjusted gross profit q2
- $1.84 million
- Total shares repurchased
- 5112000
- Adjusted gross profit yoy
- 58.4%
- Total liabilities reduction
- $6.27 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.